- Conditions
- Hailey Hailey Disease
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 39
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 32
- States / cities
- Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more
- Conditions
- Psoriasis
- Interventions
- Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 837 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 26
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 23 more
- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
- Conditions
- Healthy
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Janssen-Cilag Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- San Francisco, California • Chicago, Illinois • St Louis, Missouri + 1 more
- Conditions
- Rheumatic Disease
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
- Drug · Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spondyloarthritis, Inflammatory Bowel Diseases
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
- Conditions
- Arthritis, Psoriatic
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 38
- States / cities
- Avondale, Arizona • Chandler, Arizona • Mesa, Arizona + 35 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Giant Cell Arteritis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Boston, Massachusetts
- Conditions
- Lupus Nephritis
- Interventions
- Guselkumab Dose 1, Placebo, Guselkumab Dose 2, Standard-of-care treatment
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Covina, California • La Jolla, California • Los Angeles, California + 5 more
- Conditions
- Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Cincinnati, Ohio + 2 more
- Conditions
- Moderate Plaque Psoriasis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 34 more
- Conditions
- Psoriasis
- Interventions
- Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 109
- States / cities
- Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
- Conditions
- Psoriasis
- Interventions
- Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more
- Conditions
- Crohn Disease
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 77
- States / cities
- Dothan, Alabama • Chandler, Arizona • Scottsdale, Arizona + 65 more
- Conditions
- Healthy
- Interventions
- Guselkumab (lyophilized formulation), Guselkumab (liquid formulation with PFS-U), Guselkumab (liquid formulation with PFS FID), Guselkumab (liquid formulation)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Tempe, Arizona • Lincoln, Nebraska • Neptune City, New Jersey
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 63
- States / cities
- Arcadia, California • Coronado, California • Lancaster, California + 54 more
- Conditions
- Plaque Psoriasis, Scalp Psoriasis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more